ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$293.27
-11.35 (-3.73%)
▼
5d:
-6.04%
30d:
-8.55%
90d:
-15.26%
HOLD
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ONC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ONC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$439.82
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$273.09
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $293.27, which is considered oversold relative to its 30-day fair value range of $298.02 to $316.87. From a valuation perspective, the stock is trading at a discount (Forward PE: 32.5) compared to its historical average (41.5). Remarkably, the market is currently pricing in an annual earnings decline of 7.8% over the next few years. This pessimistic expectation contrasts with the company's recent 16970.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a downtrend. The price is currently testing key support at $293.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $411.27 (+40.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ONC is in a downtrend. The price is currently testing key support at $293.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $411.27 (+40.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$298.02 -
$316.87
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 40.2% below Wall St target ($411.27)
- CAUTION: Recommendation downgraded due to -6.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$298.02 -
$316.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$293.30
Resistance Level
$322.45
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
32.46
Wall Street Target
$411.27
(+40.2%)
Revenue Growth (YoY)
35.5%
Earnings Growth (YoY)
16970.8%
Profit Margin
8.9%
Valuation Discount vs History
-7.8% cheaper
PE vs Historical
32.5 vs 41.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.8%
(market-implied from PE analysis)
1-Year Target
$270.39
(-8%)
2-Year Target
$249.30
(-15%)
3-Year Target
$229.86
(-22%)
3-Yr Target (if PE normalizes)
(PE: 32→42)
$293.85
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 32.5, Growth: 47.6%)
$943.76
(+222%)
Base:
(SPY PE: 22.1, Growth: 47.6%)
$641.62
(+119%)
Bear:
(PE: 18.8, Growth: 47.6%)
$545.38
(+86%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (51x PE), but valuation improves significantly next year (32x PE) as earnings recover.
Forward PE: 50.76 | Forward EPS (Implied): $5.78
Bull Case
$354.12
(+21%)
Analyst growth 15.0%, PE expands to 53.3
Base Case
$293.27
(0%)
Market implied 0.0%, PE stable at 50.8
Bear Case
$224.35
(-24%)
Severe decline -15.0%, PE contracts to 45.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 32.5 to 41.5
Stabilization Target:
$374.92
(+27.8%)
PE Expansion Potential:
+27.8%
Share & Embed Analysis
Last updated: May 18, 2026 6:39 AM ET
Data refreshes hourly during market hours. Next update: 7:39 AM
Data refreshes hourly during market hours. Next update: 7:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Chan Henry Lee
SELL
1660 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 52 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |